Targeted Pulse Quiz: August 11

T-DXd receives FDA breakthrough therapy designation for HR+/HER2-low breast cancer and real-world data confirms brexu-cel’s efficacy in relapsed/refractory B-cell ALL. A New AI-based study enrolls first patient, strengths and weakness in multiple myeloma treatment are examined, and tafasitamab combination scores in FL.

Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.

Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.

Apalutamide offers a quicker, deeper PSA response vs enzalutamide in mCSPC and the SENTRY study supports SOC combination therapy for myelofibrosis. We also cover integrative oncology, which has been shown to reduce cancer-related anxiety and depression and we explore vorasidenib’s FDA approval in glioma treatment.

FDA approves afami-cel for advanced synovial sarcoma and dostarlimab is now approved for all advanced endometrial cancers. In addition, buprenorphine offers improved pain management for bone marrow transplant patients, subcutaneous amivantamab reduces AEs, and SRS offers benefits over WBRT for SCLC.

The FDA’s ODAC mandates phase assessments for NSCLC trials, dendritic cell immunotherapy shows improved survival in pancreatic cancer, and a new blood test for colorectal cancer receives FDA approval. In addition, pembrolizumab plus neoadjuvant chemo proves effective in unresectable HGSC and THIO-cemiplimab combo shows lower toxicity in advanced NSCLC.